What Happened
- Prime Minister Narendra Modi launched India's nationwide Human Papillomavirus (HPV) vaccination campaign on February 28, 2026, from Ajmer, Rajasthan.
- The programme targets approximately 1.15 crore 14-year-old girls annually, offering a free single dose of the Gardasil-4 (quadrivalent HPV) vaccine at government health facilities across all states and Union Territories.
- The campaign will initially run in a special three-month mission mode before being integrated into routine immunization services under the Universal Immunization Programme (UIP).
- Parental/guardian written consent is mandatory for participation; vaccination is voluntary. Beneficiary tracking will be managed through the U-WIN digital immunization platform.
- The campaign is led by the Ministry of Health and Family Welfare (MoHFW).
- India reports over 1.2 lakh new cervical cancer cases and approximately 80,000 deaths per year — cervical cancer is the second most common cancer among Indian women (after breast cancer).
- The Indian Medical Association (IMA) welcomed the launch, calling it a "landmark step" in preventive healthcare.
- India's domestically produced HPV vaccine — CERVAVAC (manufactured by Serum Institute of India, Pune) — was approved by CDSCO in 2022 at a fraction of imported vaccine prices; it is expected to be integrated into the program progressively.
Static Topic Bridges
Universal Immunization Programme (UIP) and India's Vaccine Architecture
India's Universal Immunization Programme (UIP), one of the world's largest public health programs, was launched in 1985 (as an expansion of the Expanded Programme on Immunization started in 1978). It currently covers vaccination against 12 vaccine-preventable diseases: Tuberculosis (BCG), Hepatitis B, Polio (OPV + IPV), Diphtheria, Pertussis, Tetanus (DPT), Haemophilus influenzae type b (Hib), Pneumococcal disease (PCV), Rotavirus, Measles, Rubella, and Japanese Encephalitis (in select districts). The addition of HPV vaccine for 14-year-old girls represents the first new vaccine added to UIP for adolescents in over a decade, and the first cancer-preventive vaccine in the program.
- UIP covers approximately 2.67 crore infants and 2.9 crore pregnant women annually
- Mission Indradhanush (launched 2014): Intensification drive to vaccinate children missed by routine UIP; targets 90%+ full immunization coverage
- Intensified Mission Indradhanush (IMI 5.0): Latest phase targeting left-behind populations in hard-to-reach areas
- U-WIN platform: Digital platform for tracking immunization — analogous to CoWIN (used for COVID-19 vaccines); stores beneficiary records, schedules appointments, generates digital certificates
- Cold chain: UIP vaccines require unbroken 2–8°C cold chain from manufacturer to last mile; India has 29,000+ cold chain points
- EVIN (Electronic Vaccine Intelligence Network): Real-time vaccine stock monitoring across cold chain points
- HPV vaccine integration: Initially mission mode (3 months), then routine UIP within school health programs
Connection to this news: The HPV campaign's route to inclusion in UIP follows the standard pathway: Cabinet/Ministry approval → dedicated mission mode rollout to build familiarity → integration into routine schedule and cold chain.
HPV, Cervical Cancer, and the Science of Prevention
Human Papillomavirus (HPV) is a group of over 200 related viruses transmitted through skin-to-skin contact, predominantly sexual. Of these, approximately 14 are "high-risk" types associated with cancer. HPV types 16 and 18 together cause approximately 70% of cervical cancers worldwide; types 6 and 11 cause the majority of genital warts. The Gardasil-4 (quadrivalent) vaccine protects against HPV types 6, 11, 16, and 18. Single-dose schedules have been validated by the WHO's Strategic Advisory Group of Experts on Immunization (SAGE) in 2022 — a critical finding that makes national programs far more logistically feasible.
- HPV vaccine efficacy: 90%+ in preventing cervical cancer if administered before first sexual exposure (hence the 14-year target age)
- Single-dose effectiveness: WHO SAGE 2022 confirmed single dose provides robust and durable protection
- Available vaccines: Gardasil-4 (Merck, quadrivalent), Cervarix (GSK, bivalent — types 16 & 18), Gardasil-9 (nonavalent — types 6, 11, 16, 18, 31, 33, 45, 52, 58)
- CERVAVAC (Serum Institute of India): Quadrivalent, CDSCO-approved January 2022; priced ~₹200/dose (vs. ₹2,000+ for imported vaccines) — designed for low/middle-income country markets; WHO prequalification sought
- India's cervical cancer burden: 1.2 lakh+ new cases/year; ~80,000 deaths/year; ranks 2nd in cancer burden among Indian women
- WHO's global strategy (2030 target): 90% HPV vaccination coverage by age 15, 70% cervical screening by age 35 and 45, 90% treatment coverage — India's program directly advances this goal
- Cervical cancer screening: PAP smear test (cytology), VIA (Visual Inspection with Acetic Acid) for resource-limited settings, HPV DNA testing
Connection to this news: Using the Gardasil-4 single-dose regimen is the logistically optimal choice for India's scale — a multi-dose schedule would have required tracking 1.15 crore girls across two visits, straining the health system. CERVAVAC's expected integration would further reduce costs.
Public Health Policy and India's Cancer Control Framework
India's approach to cancer control is governed by the National Cancer Control Programme (NCCP), launched in 1975, and its successor frameworks under the National Health Mission (NHM). The Ayushman Bharat Health and Wellness Centres (AB-HWCs) — now renamed Pradhan Mantri Jan Arogya Kendras (PMJAK) — are the first point of contact for cancer screening in rural and semi-urban areas, offering screening for three cancers: oral, breast, and cervical. The PM-JAY (Pradhan Mantri Jan Arogya Yojana) covers cancer treatment costs up to ₹5 lakh per family per year through a network of empaneled hospitals.
- National Cancer Control Programme (NCCP): 1975; revised 1984, 2004; merged into National Health Mission
- Ayushman Bharat: Two pillars — PM-JAY (health insurance, ₹5 lakh cover, 55 crore beneficiaries) + Health and Wellness Centres (preventive care at 1.6 lakh sub-centres)
- NHM (National Health Mission): Integrates NRHM (rural) + NUHM (urban); umbrella for UIP, maternal health, cancer screening
- HPV vaccination age rationale: 9–14 years is the optimal window (before sexual debut); India chose 14 as the target for school health delivery efficiency
- School Health Programme: Under Rashtriya Kishor Swasthya Karyakram (RKSK) for adolescents — school entry point for HPV delivery
- Gender dimension: Cervical cancer is entirely preventable — its high burden in India reflects gaps in screening access, health literacy, and gender-sensitive healthcare infrastructure
Connection to this news: The HPV drive operationalizes the preventive pillar of Ayushman Bharat — moving beyond curative insurance (PM-JAY) to population-level cancer prevention. Integrating delivery through schools and AB-HWCs leverages existing infrastructure.
Key Facts & Data
- Launch date: February 28, 2026; launch location: Ajmer, Rajasthan
- Target population: ~1.15 crore 14-year-old girls annually
- Vaccine: Gardasil-4 (quadrivalent HPV — types 6, 11, 16, 18); single dose
- Cost: Free at government health facilities
- India cervical cancer burden: 1.2 lakh+ new cases/year; ~80,000 deaths/year
- Cervical cancer rank: 2nd most common cancer in Indian women (after breast cancer)
- HPV types 16 & 18: Cause ~70% of cervical cancers globally
- WHO SAGE 2022: Confirmed single-dose HPV vaccination provides robust protection
- CERVAVAC (Serum Institute of India): Quadrivalent, CDSCO-approved January 2022; ~₹200/dose
- U-WIN: Digital immunization tracking platform (successor to CoWIN)
- Ministry: Ministry of Health and Family Welfare (MoHFW)
- Mission mode: Initial 3-month intensive drive → then integration into routine UIP
- PM-JAY coverage: ₹5 lakh/family/year; 55 crore beneficiaries
- WHO global cervical cancer elimination strategy: 90-70-90 targets by 2030